AbbVie Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Michael
- Full Time Employees
- 55,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
AbbVie (ABBV) Rises Higher Than Market: Key Facts
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
AbbVie: Growth-Pharma Profile At A Value-Pharma Price
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
AbbVie, Devon Energy And More On CNBC's 'Final Trades'
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
3 Dividend Stocks Built for Retirement to Buy in June
FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means
Morgan Stanley, Shake Shack, Cboe Global Markets And A Health Care Stock On CNBC's 'Final Trades'
AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades'
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?